Brief: Expres2ion To Lead European COVID-19 Vaccine Consortium For Rapid Clinical Development

ExpreS2ion Biotech Holding AB

24/02/2020 07:48

Feb 24 (Reuters) - ExpreS2ion Biotech Holding AB  EXPRS2.ST :
    * TO LEAD EUROPEAN COVID-19 VACCINE CONSORTIUM FOR RAPID CLINICAL DEVELOPMENT
    * WILL LEAD CONSORTIUM OF EUROPEAN EXPERT ENTITIES IN APPLYING FOR EU HORIZON 2020 AND
COALITION
FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI) GRANT CALLS FOR COVID-19 (SARS-COV-2) CORONAVIRUS
VACCINE DEVELOPMENT
    * CONSORTIUM INCLUDES ALL BENCH-TO-BEDSIDE EXPERTISE REQUIRED FOR RAPID CLINICAL DEVELOPMENT
OF
COVID-19 VACCINE THAT IS ALREADY UNDER DEVELOPMENT BY EXPRES2ION.
    * AIM OF CONSORTIUM IS TO DEVELOP A COVID-19 VACCINE CANDIDATE, INCLUDING PERFORMING
PROOF-OF-CONCEPT NON-HUMAN PRIMATE (NHP) CHALLENGE STUDIES, AS WELL AS A PHASE I/IIA CLINICAL
TRIAL
    * AMBITIOUS AIM IS TO INITIATE CLINICAL INVESTIGATIONS WITHIN 12 MONTHS

Source text for Eikon:  ID:nWkr2RYbrz 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))